The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | The importance of quickly spotting the signs of AML
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, notes the key biological and clinical characteristics that enable the earlier detection of AML. Monitoring symptoms of patients with characteristics such as anemia, low platelet count, and splenomegaly, would allow the early therapeutic intervention that could prevent the surprise of the more debilitating blastic phase in AML. Prof. Verstovsek strongly recommends following patients every 3-6 months for any changes in pattern of platelets and blasts to allow for the most effective treatment and improve chances of survival in patients.
